2019
Complications associated with immunotherapy for brain metastases.
Tran TT, Jilaveanu LB, Omuro A, Chiang VL, Huttner A, Kluger HM. Complications associated with immunotherapy for brain metastases. Current Opinion In Neurology 2019, 32: 907-916. PMID: 31577604, PMCID: PMC7398556, DOI: 10.1097/wco.0000000000000756.Peer-Reviewed Original ResearchConceptsBrain metastasesNeurologic toxicityImmune therapyPhase 2 clinical trialCheckpoint inhibitor therapyImmune checkpoint inhibitorsMultiple phase 2 clinical trialsTreatment-related morbidityBrain metastatic diseaseSymptomatic edemaCheckpoint inhibitorsAdverse eventsDurable responsesMedian survivalMetastatic diseaseInhibitor therapyMore patientsIntracranial activityPatient groupRadiation necrosisClinical trialsTherapy trialsMultidisciplinary teamMetastasisPatients
2011
Targeted Therapy for Malignant Gliomas
Dankwah-Quansah M, Omuro A. Targeted Therapy for Malignant Gliomas. Tumors Of The Central Nervous System 2011, 299-307. DOI: 10.1007/978-94-007-0344-5_31.Peer-Reviewed Original ResearchMalignant gliomasAggressive primary brain tumorFatal disease outcomeSingle-agent trialsSingle-agent treatmentPrimary brain tumorsAkt/mTORDevelopment of combinationsAgent trialsDismal prognosisPatient selectionStandard treatmentTargeted therapyDisease outcomeAnaplastic astrocytomaAnaplastic oligodendrogliomaBrain tumorsTherapy trialsNew treatmentsPathway inhibitionGliomasAgent treatmentTrialsRas/MAPKPromising activity